Preview Mode Links will not work in preview mode
  1. All Episodes
  2. Non-Small Cell Lung Cancer | Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation — Part 3

Non-Small Cell Lung Cancer | Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation — Part 3

Oct 31, 2022

Featuring perspectives from Dr Pasi Jänne, including the following topics:

  • Introduction: Journal Club with Pasi A Jänne, MD, PhD — Part 1 (0:00)
  • Case: An Asian man in his late 60s with adenocarcinoma of the lung and pleural effusion with EGFR amplification (PD-L1 20%) — Jennifer L Dallas, MD (12:33)
  • Case: A man in his late 50s with metastatic adenocarcinoma of the lung with discordant EGFR testing results and a new mediastinal lesion after therapy with osimertinib — Rohit Gosain, MD (16:10)
  • Case: A man in his late 40s with metastatic adenocarcinoma of the lung and a brain metastasis with an EGFR exon 19 mutation and disease progression after stereotactic body radiation therapy (SBRT) and osimertinib, now with an ALK mutation by RNA testing (PD-L1 0) — Namrata I Peswani, MD (18:44)
  • Case: A man in his early 50s with Stage III unresectable adenocarcinoma of the lung with an EGFR mutation who receives chemoradiation therapy and consolidation durvalumab, now with metastatic recurrence — Ferdy Santiago, MD (21:51)
  • Case: A man in his early 70s with Stage IIIC large cell neuroendocrine carcinoma of the lung and an EGFR S768I mutation (PD-L1 1%) — Jarushka Naidoo, MB BCH, MHS (28:17)
  • Case: A man in his early 80s with metastatic adenocarcinoma of the lung with an EGFR exon 20 insertion mutation and disease progression on mobocertinib — Jiaxin (Jason) Niu, MD, PhD (32:15)
  • Case: A woman in her mid 70s with adenocarcinoma of the lung and an EGFR exon 20 insertion mutation with new bone and brain metastases after therapy with osimertinib — Dr Niu (37:11)
  • Journal Club with Dr Jänne — Part 2 (43:02)
  • Case: A woman in her mid 80s with metastatic adenocarcinoma of the lung with an EGFR exon 21 mutation who switched to erlotinib due to osimertinib-related toxicities, now with recurrence at the primary site (PD-L1 10%) — John Yang, MD (55:18)
  • Case: An Asian man in his early 70s with metastatic adenocarcinoma of the lung with an EGFR exon 19 deletion and brain metastases who receives SBRT and osimertinib but develops extracranial biopsy-proven small cell lung cancer progression — Dr Niu (58:35)

CME information and select publications